HOME >> MEDICINE >> NEWS
NIAID launches program to improve medical tools against emerging infectious diseases

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded 14 contracts totaling more than $73 million to fund the Large-Scale Antibody and T Cell Epitope Discovery Program, an initiative aimed at quickly identifying the regions of selected infectious agents that elicit immune reactions. The study of these regions, known as epitopes, promises to uncover targets for new and improved vaccines, therapies and diagnostic tools against potential bioterror agents as well as emerging/re-emerging infectious diseases such as West Nile virus and influenza. NIAID will make information on each newly identified epitope freely available to scientists through a searchable online database currently under development.

"Elucidating the basic mechanisms of immune function is a major focus of our biodefense research agenda," says Anthony S. Fauci, M.D., director of NIAID. "The information generated by this program will deepen our understanding of how components of the immune system defend against certain infectious agents, enabling researchers to design new and improved medical countermeasures."

"Researchers have been conducting epitope discovery for many years, but generally on a small scale," says Daniel Rotrosen, M.D., director of NIAID's Division of Allergy, Immunology and Transplantation. "This initiative, however, will yield new knowledge about antigenic epitopes from a wide variety of microbes, including agents that might be used in a bioterrorist attack."

Epitopes are recognized by the body's B and T cells, white blood cells that detect an invading pathogen. Each B and T cell is specific for a particular antigen, meaning that each can only bind to a certain foreign molecular structure. This "specificity" is determined by the receptors on the surface of each cell.

Both B- and T-cell specificity as well as the diverse functions of these cells determine the effectiveness of an immu
'"/>

Contact: Paul Williams
pw81y@nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
1-Nov-2004


Page: 1 2 3

Related medicine news :

1. NIAID initiates trial of experimental avian flu vaccine
2. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks
3. NIAID begins enrolling volunteers for novel HIV vaccine study
4. NIAID-sponsored clinical trial aims to boost flu vaccine supply
5. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks
6. NIAID launches influenza genome sequencing project
7. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine
8. NIAID rotavirus vaccine licensed for commercialization
9. Second NIAID SARS vaccine candidate helps mice fend off SARS
10. NIAID vaccine protects against SARS virus infection in mice
11. NIAID Ebola vaccine enters human trial

Post Your Comments:
(Date:10/31/2014)... (PRWEB) October 31, 2014 Springboard ... for its small scale BioPro™ biodiesel processors, announced ... will further improve the performance and efficiency of ... GL95/MC12/BD380 trio will recover more than ... in with the glycerin by-product produced while making ...
(Date:10/31/2014)... The Memory Healer review published by DailyGossip.org reveals that ... suffered from Alzheimer's disease. , In fact, Alexander Lynch ... disease. His father pointed a gun and shot him during ... author of this method understood that he needed to do ... program is based on years of research. The author of ...
(Date:10/31/2014)... 2014 At the start of 2014, ... escaping carbon monoxide poisoning in their homes. Now, as ... one family-owned, Missouri-based heating and cooling company is taking ... families start the home heating season with the assurance ... , Beginning Nov. 1, 2014, E and Q Heating ...
(Date:10/31/2014)... Oct. 31, 2014 (HealthDay News) -- Surgery for low ... where in the United States you live, a new ... experience low back pain at some point in their ... professional medical care for a spine problem," co-author Brook ... Clinical Practice, said in a college news release. ...
(Date:10/31/2014)... insomnia is a major contributor to deaths caused by ... results underscore the importance of the "Sleep Well, Be ... , Results show that the risk of unintentional fatal ... of insomnia symptoms present. People with all three symptoms ... from a fatal injury than those with no insomnia ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:"Memory Healer" Review Reveals a New Natural Remedy Guide for Managing Memory Loss 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 2Health News:Many Homeowners Missing Key Safety Risks with Home Heating;Missouri-based Company E and Q Announces New Safety Check 3Health News:Spinal Surgery Varies by Region in U.S.: Study 2Health News:Insomnia increases risk of motor vehicle deaths, other fatal injuries 2
(Date:10/31/2014)...  Digirad Corporation (Nasdaq: DRAD) today announced that it has ... PDII ), a healthcare commercialization services company, responding to ... company.  Digirad calls upon PDI to ... to operate in the ordinary course of business and ... debt, on acquisitions or other extraordinary transactions. Digirad believes ...
(Date:10/31/2014)... Oct. 31, 2014 Mast Therapeutics, Inc. (NYSE ... results for the quarter ended September 30, 2014. ... Officer, said:  "The third quarter was productive for Mast. Consistent ... of MST-188 for sickle cell disease is on track ... now have opened 50 study sites in the U.S. ...
(Date:10/31/2014)... , October 31, 2014 ... Corporation (NASDAQ: CELG ), Bristol-Myers Squibb Co. ... UNH ), Sanofi SA (NYSE: ... members receive these notes ahead of publication. To reserve ... . , ,-- ,Celgene Corporation Research Reports ,On October ...
Breaking Medicine Technology:Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 2Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 3Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 4Digirad Delivers Letter To PDI, Inc. Responding To PDI's Summary Rejection Of Digirad's Offer To Acquire Company 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 2Mast Therapeutics Reports Third Quarter 2014 Financial Results 3Mast Therapeutics Reports Third Quarter 2014 Financial Results 4Mast Therapeutics Reports Third Quarter 2014 Financial Results 5Mast Therapeutics Reports Third Quarter 2014 Financial Results 6Mast Therapeutics Reports Third Quarter 2014 Financial Results 7Mast Therapeutics Reports Third Quarter 2014 Financial Results 8Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 2Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 3Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 4Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 5Financial Results, Acquisition Agreement, and Legal Issue Update - Research Reports on Celgene, Bristol-Myers, UnitedHealth, Sanofi and Actavis 6
Cached News: